EE183 Cost-Effectiveness Analysis of Early Versus Delayed Use of Abemaciclib Combination Treatment in Patients with HR+/HER2- High-Risk Early Breast Cancer: A US Payer Perspective

Abstract

Clinical guidelines recommend use of abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, in combination with endocrine therapy (ET) as adjuvant treatment for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) early breast cancer (EBC) at high risk of recurrence or in combination with fulvestrant if patients develop metastatic breast cancer (MBC). We evaluated the cost-effectiveness of early use of abemaciclib and ET combination as first-line adjuvant therapy and then use of fulvestrant after developing MBC (early use) versus ET treatment in EBC followed by delayed use of combination abemaciclib and fulvestrant in MBC (delayed use).